Daxor Corporation announced a new research letter in the Journal of the American College of Cardiology â Heart Failure validating the benefits of the Companyâs BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. The study, titled âDiscordant Pressure-Volume Trends During CardioMEMS Monitoring,â evaluated the correlation of pressure-volume profiles over two time periods in a series of heart failure (HF) patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxorâs blood volume analysis (BVA) diagnostic.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.65 USD | -2.92% | -1.03% | +0.52% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.52% | 46.38M | |
+3.74% | 12.61B | |
+5.50% | 9.01B | |
-3.20% | 5.41B | |
+5.63% | 5.19B | |
+2.44% | 5.25B | |
+14.36% | 4.48B | |
+16.67% | 4.44B | |
+1.53% | 4B | |
+1.56% | 3.75B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy